TSHA Annual CFF
$136.39 M
+$84.30 M+161.81%
31 December 2023
Summary:
As of January 23, 2025, TSHA annual cash flow from financing activities is $136.39 million, with the most recent change of +$84.30 million (+161.81%) on December 31, 2023. During the last 3 years, it has fallen by -$154.67 million (-53.14%). TSHA annual CFF is now -53.14% below its all-time high of $291.06 million, reached on December 31, 2020.TSHA Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TSHA Quarterly CFF
$6.59 M
-$63.87 M-90.64%
30 September 2024
Summary:
As of January 23, 2025, TSHA quarterly cash flow from financing activities is $6.59 million, with the most recent change of -$63.87 million (-90.64%) on September 30, 2024. Over the past year, it has dropped by -$134.04 million (-95.31%). TSHA quarterly CFF is now -97.59% below its all-time high of $274.18 million, reached on September 30, 2020.TSHA Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TSHA TTM CFF
$72.79 M
-$134.04 M-64.81%
30 September 2024
Summary:
As of January 23, 2025, TSHA TTM cash flow from financing activities is $72.79 million, with the most recent change of -$134.04 million (-64.81%) on September 30, 2024. Over the past year, it has dropped by -$109.08 million (-59.98%). TSHA TTM CFF is now -75.12% below its all-time high of $292.55 million, reached on September 30, 2020.TSHA TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TSHA Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +161.8% | -95.3% | -60.0% |
| 3 y3 years | -53.1% | -78.0% | +155.4% |
| 5 y5 years | - | - | - |
TSHA Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +249.0% | -95.3% | +255.3% | -64.8% | +264.5% |
| 5 y | 5-year | -53.1% | +249.0% | -97.6% | +255.3% | -75.1% | +303.8% |
| alltime | all time | -53.1% | +249.0% | -97.6% | +255.3% | -75.1% | +303.8% |
Taysha Gene Therapies Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $6.59 M(-90.6%) | $72.79 M(-64.8%) |
| June 2024 | - | $70.47 M(<-9900.0%) | $206.83 M(+51.3%) |
| Mar 2024 | - | -$22.00 K(-99.5%) | $136.74 M(+0.3%) |
| Dec 2023 | $136.39 M(+161.8%) | -$4.25 M(-103.0%) | $136.39 M(-25.0%) |
| Sept 2023 | - | $140.63 M(>+9900.0%) | $181.87 M(+342.1%) |
| June 2023 | - | $377.00 K(-201.9%) | $41.14 M(-20.6%) |
| Mar 2023 | - | -$370.00 K(-100.9%) | $51.83 M(-0.5%) |
| Dec 2022 | $52.10 M | $41.23 M(<-9900.0%) | $52.10 M(+160.9%) |
| Sept 2022 | - | -$103.00 K(-100.9%) | $19.97 M(-60.1%) |
| June 2022 | - | $11.07 M(<-9900.0%) | $50.05 M(+28.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | -$107.00 K(-101.2%) | $38.98 M(-0.3%) |
| Dec 2021 | $39.08 M(-86.6%) | $9.11 M(-69.6%) | $39.08 M(+37.2%) |
| Sept 2021 | - | $29.98 M(>+9900.0%) | $28.50 M(-89.6%) |
| June 2021 | - | $0.00(0.0%) | $272.70 M(-0.1%) |
| Mar 2021 | - | $0.00(-100.0%) | $273.04 M(-6.2%) |
| Dec 2020 | $291.06 M | - | - |
| Dec 2020 | - | -$1.48 M(-100.5%) | $291.06 M(-0.5%) |
| Sept 2020 | - | $274.18 M(>+9900.0%) | $292.55 M(+1493.0%) |
| June 2020 | - | $338.00 K(-98.1%) | $18.36 M(+1.9%) |
| Mar 2020 | - | $18.03 M | $18.03 M |
FAQ
- What is Taysha Gene Therapies annual cash flow from financing activities?
- What is the all time high annual CFF for Taysha Gene Therapies?
- What is Taysha Gene Therapies annual CFF year-on-year change?
- What is Taysha Gene Therapies quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Taysha Gene Therapies?
- What is Taysha Gene Therapies quarterly CFF year-on-year change?
- What is Taysha Gene Therapies TTM cash flow from financing activities?
- What is the all time high TTM CFF for Taysha Gene Therapies?
- What is Taysha Gene Therapies TTM CFF year-on-year change?
What is Taysha Gene Therapies annual cash flow from financing activities?
The current annual CFF of TSHA is $136.39 M
What is the all time high annual CFF for Taysha Gene Therapies?
Taysha Gene Therapies all-time high annual cash flow from financing activities is $291.06 M
What is Taysha Gene Therapies annual CFF year-on-year change?
Over the past year, TSHA annual cash flow from financing activities has changed by +$84.30 M (+161.81%)
What is Taysha Gene Therapies quarterly cash flow from financing activities?
The current quarterly CFF of TSHA is $6.59 M
What is the all time high quarterly CFF for Taysha Gene Therapies?
Taysha Gene Therapies all-time high quarterly cash flow from financing activities is $274.18 M
What is Taysha Gene Therapies quarterly CFF year-on-year change?
Over the past year, TSHA quarterly cash flow from financing activities has changed by -$134.04 M (-95.31%)
What is Taysha Gene Therapies TTM cash flow from financing activities?
The current TTM CFF of TSHA is $72.79 M
What is the all time high TTM CFF for Taysha Gene Therapies?
Taysha Gene Therapies all-time high TTM cash flow from financing activities is $292.55 M
What is Taysha Gene Therapies TTM CFF year-on-year change?
Over the past year, TSHA TTM cash flow from financing activities has changed by -$109.08 M (-59.98%)